Abstract
Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Current Respiratory Medicine Reviews
Title: New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III
Volume: 3 Issue: 2
Author(s): Marcus B. Conde and Margarita Elsa Villarino
Affiliation:
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Abstract: Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Export Options
About this article
Cite this article as:
Conde B. Marcus and Elsa Villarino Margarita, New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III, Current Respiratory Medicine Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339807780599144
DOI https://dx.doi.org/10.2174/157339807780599144 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Ultrasonic and Microwave Assisted Synthesis of Nitrogen-Containing Derivatives of Juglone as Potential Antibacterial Agents
Letters in Organic Chemistry Is COVID-19 a Systemic Disease?
Coronaviruses The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment
Current Drug Delivery Appropriate Antibiotic Prescribing Pattern in Hospitalized Children
Current Drug Safety Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Antimicrobial Peptide Precursor Structures Suggest Effective Production Strategies
Recent Patents on Inflammation & Allergy Drug Discovery Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review
Current Topics in Medicinal Chemistry Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Transition States and Inhibitors of the Purine Nucleoside Phosphorylase Family
Current Topics in Medicinal Chemistry The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Carbohydrate Mimics and Lectins: A Source of New Drugs and Therapeutic Opportunities
Mini-Reviews in Medicinal Chemistry Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy